Results 211 to 220 of about 21,458 (231)
Some of the next articles are maybe not open access.

Botulinum Toxin Type A in Dental Medicine

Journal of Dental Research, 2019
Botulinum toxins (BoNTs) are a product of the bacteria Clostridium botulinum. By entering nerve endings, they cleave and inactivate SNARE proteins, which are essential for neurotransmitter release. Prevention of acetylcholine release at the neuromuscular junction causes long-lasting and potentially fatal flaccid paralysis—a major feature of botulism ...
A.A. Del Bel Cury   +4 more
openaire   +3 more sources

Botulinum toxin type A in the treatment of Raynaud's phenomenon

Dermatologic Therapy, 2020
Raynaud's phenomenon is a vasospastic disorder clinically characterized by cold or stress-induced discoloration of the skin, pain and ulcers of the fingers or toes. Although this phenomenon might be self-limiting, there is a subgroup of patients requiring a therapeutic approach.
S. Meelad Habib   +4 more
openaire   +4 more sources

Botulinum Toxin Type A for Chronic Migraine

Current Neurology and Neuroscience Reports, 2010
Chronic migraine (CM) is the leading cause of chronic daily headache, a common and debilitating headache syndrome. The management of CM patients is challenging, with only limited benefit from available oral preventive medications. Botulinum neurotoxin (BoNT) has been used extensively to treat disorders associated with increased muscle tone. More recent
openaire   +2 more sources

Botulinum toxin type A in chronic migraine

Expert Review of Neurotherapeutics, 2007
The use of botulinum toxin type A continues to be investigated by the US FDA for potential use in the treatment of headache. As part of this process there has been extensive research conducted by individual study sites as well as multicenter trials. To date, the majority of the focus has been on migraine headache as well as on tension-type headache ...
openaire   +2 more sources

Botulinum toxin type A for treatment of hyperhidrosis [PDF]

open access: possibleTherapy, 2005
Hyperhidrosis is defined as excessive sweating beyond that required to return the body temperature to normal. Focal hyperhidrosis commonly affects the axillae, palms, soles or face and often has a tremendous psychosocial and occupational impact on affected patients.
openaire   +1 more source

Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy

Movement Disorders, 2002
AbstractIn some patients, therapy with botulinum toxin type A (BT‐A) becomes ineffective due to formation of antibodies (BT‐A‐AB). The time course of BT‐A‐AB titres after cessation of BT‐A therapy was quantitatively studied to determine whether and when they might drop.
Hans Bigalke, Dirk Dressler
openaire   +2 more sources

Botulinum toxin type A [PDF]

open access: possibleInpharma Weekly, 1999
‘Poison can be employed as a means for destruction of life or as a treatment for the sick’. Such is the case with botulinum toxin type A, said Dr Roger Aoki from Allergan Inc., US, speaking at the 4th Congress of the European Federation of Neurological Societies [Lisbon, Portugal; September 1999].
openaire   +1 more source

Detoxification of Crystalline Botulinum Type A Toxin

The Journal of Immunology, 1947
Summary Botulinum Type A toxoid has been prepared from crystalline toxin by the addition of formaldehyde. The most active preparation consisted of one component electrophoretically, immunized mice in a dose containing 0.01γ of toxoidnitrogen and was 2400 times more active antigenically than crude toxoid on the basis of nitrogen-content.
G A, HOTTLE, A, ABRAMS
openaire   +2 more sources

Pharmacology and immunology of botulinum toxin type A

Clinics in Dermatology, 2003
The utility of botulinum neurotoxins as therapeutic and esthetic agents depends on their ability to inhibit neurotransmitter release from selected neurons, remain localized at the site of injection, and evade the body's immunologic defenses. The clinical correlates of these actions, respectively, are efficacy, safety, and a low rate of antibody ...
openaire   +3 more sources

Botulinum toxin type A for the treatment of migraine

Expert Opinion on Pharmacotherapy, 2006
Migraine is a common and debilitating disorder that often requires prophylactic therapy, particularly for those migraine patients who meet the diagnostic criteria for chronic daily headache (chronic migraine). Existing prophylactic treatments for migraine are inadequate for many patients due to their modest efficacy and/or systemic side effects ...
openaire   +3 more sources

Home - About - Disclaimer - Privacy